Astex's Pyramid Scheme

Astex's latest deal with Schering further distances the firm from infrastructure-heavy structural biology players. Astex hopes that by applying its fragment-based approach to solving key discovery problems among a handful of much sought-after targets-rather than solving many target structures or offering its capability on a service basis-it can sign higher value deals and prevent itself from becoming a victim of the field's commoditization.